Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities: 2014-2024

Historic Total Non-Current Liabilities for Vanda Pharmaceuticals (VNDA) over the last 11 years, with Dec 2024 value amounting to $108.1 million.

  • Vanda Pharmaceuticals' Total Non-Current Liabilities rose 31.21% to $124.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.1 million, marking a year-over-year increase of 31.21%. This contributed to the annual value of $108.1 million for FY2024, which is 14.12% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $108.1 million for FY2024, which was up 14.12% from $94.7 million recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $108.1 million for FY2024, and its period low was $77.4 million during FY2020.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $100.2 million (2022), whereas its average is $101.0 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Total Non-Current Liabilities grew by 18.67% in 2022, and later fell by 5.53% in 2023.
  • Vanda Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $77.4 million in 2020, then grew by 9.09% to $84.5 million in 2021, then increased by 18.67% to $100.2 million in 2022, then fell by 5.53% to $94.7 million in 2023, then climbed by 14.12% to $108.1 million in 2024.